Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback